However, if the mutation occurs in exon 17 (as is often the case in seminomas and leukemias), the receptor is not inhibited by imatinib.
Porén, se a mutación ocorre no exón 17 (frecuente en seminomas e leucemias), o receptor non é inhibido polo imatinib.